Although INSTI-based regimens are highly efficacious for viral suppression, they appear to
cause more weight gain and treatment emergent obesity than non-INSTI-based regimens …

There is a growing body of evidence from both observational and randomised trials
implicating integrase inhibitors, particularly dolutegravir and bictegravir, with the …

Background: Studies have shown an increase in weight among people living with HIV
(PLWH) who initiated integrase strand transfer inhibitors (INSTI). However, weight gain with …

The Rio Grande Valley (RGV) in South Texas has one of the highest prevalence of obesity
and type 2 diabetes (T2D) in the United States (US). We report for the first time the T2D …

An observational cohort study was conducted with data from the Observational Pharmaco-
Epidemiology Research & Analysis (OPERA) cohort to investigate weight gain among …

Background Antiretroviral therapy (ART) is associated with weight gain, but this has been
shown to be more marked with dolutegravir and other integrase strand transfer inhibitors …

In 2019, there were around 38 million people living with HIV (PLHIV) worldwide. For the past
decade, new HIV infections have been reduced by 23% and AIDS-related deaths have been …

Introduction Integrase strand transfer inhibitor-based regimens (eg, containing dolutegravir
[DTG]) are associated with weight/body mass index (BMI) increases among people living …

Background Bifurcation lesions represent 15–20% of all patients undergoing a
percutaneous coronary intervention (PCI) for coronary artery disease. The provisional 1 …

Weight rose, sometimes substantially, in a single-center US analysis of people switching
from a nonnucleoside (NNRTI) or a protease inhibitor (PI) to an integrase inhibitor [1]. But …